Literature DB >> 20833719

Human beta-synuclein rendered fibrillogenic by designed mutations.

Shahin Zibaee1, Graham Fraser, Ross Jakes, David Owen, Louise C Serpell, R Anthony Crowther, Michel Goedert.   

Abstract

Filamentous inclusions made of α-synuclein are found in nerve cells and glial cells in a number of human neurodegenerative diseases, including Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. The assembly and spreading of these inclusions are likely to play an important role in the etiology of common dementias and movement disorders. Both α-synuclein and the homologous β-synuclein are abundantly expressed in the central nervous system; however, β-synuclein is not present in the pathological inclusions. Previously, we observed a poor correlation between filament formation and the presence of residues 73-83 of α-synuclein, which are absent in β-synuclein. Instead, filament formation correlated with the mean β-sheet propensity, charge, and hydrophilicity of the protein (global physicochemical properties) and β-strand contiguity calculated by a simple algorithm of sliding averages (local physicochemical property). In the present study, we rendered β-synuclein fibrillogenic via one set of point mutations engineered to enhance global properties and a second set engineered to enhance predominantly β-strand contiguity. Our findings show that the intrinsic physicochemical properties of synucleins influence their fibrillogenic propensity via two distinct but overlapping modalities. The implications for filament formation and the pathogenesis of neurodegenerative diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833719      PMCID: PMC2992288          DOI: 10.1074/jbc.M110.160721

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

Authors:  B I Giasson; I V Murray; J Q Trojanowski; V M Lee
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

2.  Relative influence of hydrophobicity and net charge in the aggregation of two homologous proteins.

Authors:  Martino Calamai; Niccolo Taddei; Massimo Stefani; Giampietro Ramponi; Fabrizio Chiti
Journal:  Biochemistry       Date:  2003-12-30       Impact factor: 3.162

3.  Rationalization of the effects of mutations on peptide and protein aggregation rates.

Authors:  Fabrizio Chiti; Massimo Stefani; Niccolò Taddei; Giampietro Ramponi; Christopher M Dobson
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

4.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

5.  Detecting hidden sequence propensity for amyloid fibril formation.

Authors:  Sukjoon Yoon; William J Welsh
Journal:  Protein Sci       Date:  2004-08       Impact factor: 6.725

6.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

Authors:  Marie-Christine Chartier-Harlin; Jennifer Kachergus; Christophe Roumier; Vincent Mouroux; Xavier Douay; Sarah Lincoln; Clotilde Levecque; Lydie Larvor; Joris Andrieux; Mary Hulihan; Nawal Waucquier; Luc Defebvre; Philippe Amouyel; Matthew Farrer; Alain Destée
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

7.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

Authors:  P Ibáñez; A-M Bonnet; B Débarges; E Lohmann; F Tison; P Pollak; Y Agid; A Dürr; A Brice
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.

Authors:  Hai-Ning Du; Lin Tang; Xiao-Ying Luo; Hong-Tao Li; Jun Hu; Jia-Wei Zhou; Hong-Yu Hu
Journal:  Biochemistry       Date:  2003-07-29       Impact factor: 3.162

9.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

10.  The elongation of yeast prion fibers involves separable steps of association and conversion.

Authors:  Thomas Scheibel; Jesse Bloom; Susan L Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  4 in total

1.  Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils.

Authors:  Jacob I Ayers; Mieu M Brooks; Nicola J Rutherford; Jasie K Howard; Zachary A Sorrentino; Cara J Riffe; Benoit I Giasson
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

2.  The prion hypothesis of Parkinson's disease.

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

3.  The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease.

Authors:  Youssra K Al-Hilaly; Luca Biasetti; Ben J F Blakeman; Saskia J Pollack; Shahin Zibaee; Alaa Abdul-Sada; Julian R Thorpe; Wei-Feng Xue; Louise C Serpell
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

Review 4.  The Synucleinopathies: Twenty Years On.

Authors:  Michel Goedert; Ross Jakes; Maria Grazia Spillantini
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.